Patents Issued in July 25, 2024
-
Publication number: 20240245586Abstract: A cosmetic lipstick based on a glycerin-in-oil emulsion comprising (a) Diisostearoyl Polyglyceryl-3 Dimer Dilinoleate, (b) Polyglyceryl-4 Diisostearate/Polyhydroxystearate/Sebacate, (c) sunflower wax, (d) carnauba wax. The emulsion is free of mineral oil, paraffin wax, microcrystalline wax, shellac wax, polyethylene waxes, polyacrylates and crosslinked acrylate/C10-C30 alkyl acrylate polymers.Type: ApplicationFiled: January 16, 2024Publication date: July 25, 2024Inventors: Jessica RATHSACK, Tanja HARTWIG, Dorothe FIEDLER
-
Publication number: 20240245587Abstract: At least one embodiment relates to a method for making cosmetic emulsions comprising the steps of preparing a uniform (suspension) dispersion of at least one water soluble polymer in a mixture containing at least one fatty alcohol. The mixture is to be sufficiently uniform to be processed by flaking, pastillating, prilling or otherwise solidifying the mixture which is then to be added to a cosmetic emulsion oil phase before combining with a water phase.Type: ApplicationFiled: April 4, 2024Publication date: July 25, 2024Applicant: Suncoast Products LLCInventor: John Clyde CARSON
-
Publication number: 20240245588Abstract: Provided is an iron oxide pigment that is for compounding with a cosmetic composition, exhibits a large a value and/or value and a high chroma even in areas with low luminance, and has high coloring power. The iron oxide pigment for a cosmetic composition comprises a spinel structure or a spinel structure and a corundum structure, has an elemental Fe content of 680-702 g/kg, an FeO content of 30 g/kg or less, an Fe2O3 content of 939 g/kg or more, and a total content of 968 g/kg or more of FeO and Fe2O3.Type: ApplicationFiled: March 25, 2022Publication date: July 25, 2024Applicant: Titan Kogyo Kabushiki KaishaInventors: Akira YOSHIMI, Akihiko TAKADA
-
Publication number: 20240245589Abstract: A cosmetic ink composition comprises a particulate material, a polymeric dispersant, a rheology modifier, and a surface tension modifier, wherein the surface tension modifier is selected from the group consisting of C1-C16 alcohols, C5-C18 diols, and mixtures thereof. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a surface tension of from about 20 to about 45 mN/m.Type: ApplicationFiled: February 16, 2024Publication date: July 25, 2024Inventors: Janette Villalobos LINGOES, Thomas Elliot RABE, Matthew Joseph LINSER, Travis Kyle HODGDON, Ajay SUTHAR
-
Publication number: 20240245590Abstract: Aqueous reshaping compositions for keratin fibers, two-chamber packaging devices, kits-of-parts, and reshaping processes are provided, wherein said compositions have a pH in the range of 1 to 4 and comprise a) one or more bidentate or tridentate carboxylic acid, and/or their salt(s), and/or their hydrates, and/or their mixtures, and b) one or more one or more amino acid(s), and/or their salt(s), and/or mixtures of 1) and 2), wherein the total concentration of compound(s) according to group a) is 1% by weight or more, calculated to the total weight of the composition.Type: ApplicationFiled: May 13, 2022Publication date: July 25, 2024Applicant: KAO GERMANY GMBHInventors: Bernd NÖCKER, Steven BREAKSPEAR, Stephanie ILHAM
-
Publication number: 20240245591Abstract: Personal care compositions for improving the appearance and/or health of skin are provided herein. In accordance with an aspect, provided is a personal care formulation comprising an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid comprising gluconodeltalactone. According to another aspect, a personal care formulation is provided that comprises an alpha hydroxy acid; a beta hydroxy acid; and polyhydroxy acid, wherein the personal care formulation has a weight ratio of alpha hydroxy acid to polyhydroxy acid is about 5:1 to about 1:4, and wherein the personal care formulation has a weight ratio of beta hydroxy acid to polyhydroxy acid is about 1:1 to about 1:11.Type: ApplicationFiled: April 2, 2024Publication date: July 25, 2024Applicant: Colgate-Palmolive CompanyInventors: Melissa MOY, Ewelina Lesniak, Kristina Fabijanic
-
Publication number: 20240245592Abstract: The present invention relates to an emulsion or oil-dispersion cosmetic composition comprising wax, a powder, and a fatty acid ester surfactant, wherein the powder is included in 20 wt % or more relative to the total weight of the composition, and can provide a composition which contains a high content of powder, has excellent dispersibility by preventing the agglomeration of the powder due to wax, has improved filling properties of the powder, and has excellent fluidity at a high temperature.Type: ApplicationFiled: May 9, 2022Publication date: July 25, 2024Applicants: LG Household & Health Care Ltd., LG Household & Health Care Ltd.Inventors: Il Shin Maeng, Jae Sik Han
-
Publication number: 20240245593Abstract: A cooling formulation having an effective amount of an active cooling agent that modulates TRPM8 receptors, wherein the active cooling agent includes 5-10%, by volume, menthyl ethylamido oxalyate; an effective amount of UV protective agents that provide an SPF of at least 30; and further comprising 5-10% cooling oil.Type: ApplicationFiled: January 23, 2024Publication date: July 25, 2024Inventor: Linda Mullens
-
Publication number: 20240245594Abstract: The present disclosure relates to an emulsifier composition for preparing an oil-in-water emulsion and an oil-in-water emulsion composition that can form a clean beauty emulsion system. In an aspect, since the oil-in-water emulsion composition as disclosed herein does not comprise an emulsifier derived from a synthetic-based polymer, it can provide a non-sticky feel so that customers can use it with confidence.Type: ApplicationFiled: January 16, 2024Publication date: July 25, 2024Applicant: AMOREPACIFIC CORPORATIONInventors: Geunhyuk JANG, Bongsoo PI, Jin NAM, Jaewon YOU
-
Publication number: 20240245595Abstract: The present invention provides a placenta-mimic cosmetic composition which shows excellent skin improvement effects such as whitening, elasticity improvement, wrinkle improvement, moisturizing, or skin soothing by, instead of directly using the placenta containing ingredients that have legal, ethical, and safety issues, adding HEPES to PDRN, which is a major component of the placenta, and adding peptides, amino acids, or vitamins to same to recombine.Type: ApplicationFiled: June 2, 2022Publication date: July 25, 2024Applicant: LG HOUSEHOLD & HEALTH CARE LTD.Inventors: Yun Hee CHANG, Mu Hyun JIN
-
Publication number: 20240245596Abstract: One or more techniques and/or systems are disclosed for formulating a skin care product to mitigate aging or to restore damaged skin. One skin care product includes a blend of growth factors, peptides, and amino acids. Also disclosed is a skin care product formed from a synthesized protein matrix. The synthesized protein matrix can mimic the regenerative effects of human placental proteins, which are desirable when applied to skin because, as skin loses its regenerative properties, humans shows signs of aging, and a decrease in healing capabilities. The exemplary skin-care products disclosed herein can be applied to skin to help mitigate this skin aging process or to restore damaged skin.Type: ApplicationFiled: March 4, 2024Publication date: July 25, 2024Applicant: Eighth Day Labs, LLCInventor: Tony Nakhla
-
Publication number: 20240245597Abstract: The invention relates to a personal care product for alleviating skin dryness, including facial skin dryness, body dryness, and breast skin dryness and for use as a massage oil. Embodiments of the personal care product include a formulation including cocoa butter, kokum butter, shea olein, and hyaluronic acid and/or cannabis oil. The personal care product may also include other plant-based glycerides, natural hormones, herbal roots and oils, amino acids, dietary supplements. The personal care product is substantially free of added water, alcohol, synthetic chemical, anti-microbial, and synthetic hormone.Type: ApplicationFiled: March 25, 2024Publication date: July 25, 2024Applicant: DVA INC.Inventors: Gardiner FH SMITH, Chia Chia SUN
-
Publication number: 20240245598Abstract: The present invention relates to a process for making an extract of Linum usitatissimum seeds. Furthermore, it relates to the extract itself and to a cosmetic composition comprising this extract. Furthermore, it relates to the use of this extract or of the cosmetic composition comprising this extract for hair styling or for conditioning or for protection against UV radiation.Type: ApplicationFiled: September 9, 2022Publication date: July 25, 2024Inventors: Sandra Mack, David Graham, Markus Weissenegger, Juergen Falkowski, Antje Zimny
-
Publication number: 20240245599Abstract: An aftershave composition in the form of a lotion or cream for preventing razor burns, irritation, and skin dehydration caused due to shaving. The composition is easy to use and contains natural and organic components. The composition includes water, ethanol, aloe vera, fragrance, polyethylene glycol, tea tree oil, citric acid, triethanolamine, and hydrogen peroxide. The composition can be applied to any area of the body after a shave for moisturizing and hydrating skin and preventing razor burns. The composition can be used by individuals of all genders.Type: ApplicationFiled: January 11, 2024Publication date: July 25, 2024Inventor: Melwyn Turner
-
Publication number: 20240245600Abstract: An Orris root extract is disclosed. The Orris root extract is obtained via Orris root materials via selective extraction, and is selectively enriched in (A) a phytochemical melanogenesis stimulating agent or (B) a phytochemical melanogenesis inhibiting agent. The phytochemical melanogenesis stimulating agent (A) comprises germanaism B, and the phytochemical melanogenesis inhibiting agent (B) comprises iriflorental and/or iripallidal. A method of preparing the Orris root extract composition is also provided, and includes selectively extracting an Orris root materials to give at least one Orris root extract. A functional composition comprising the Orris root extract is also provided. The functional composition is adapted for administration to a subject via topical application, and demonstrates activity relating to skin pigmentation.Type: ApplicationFiled: June 2, 2022Publication date: July 25, 2024Inventors: Lisa A. ROZGA, Mickeala TU, Stephen R. MISSLER, Sunghan YIM, Timothy MULDER, Rhonda SOLBERG, Alexandria SMITH, Sudhir BASWAN
-
Publication number: 20240245601Abstract: A method of treating skin in a subject is provided. A method of reducing an appearance or effect of aging in a subject is also provided. Methods of improving skin integrity and/or skin surface topology in a subject are further provided. The methods comprise administering an effective amount of a preparation comprising ammonia oxidizing microorganisms to the subject. Related preparations and kits are also provided.Type: ApplicationFiled: April 3, 2024Publication date: July 25, 2024Inventors: Todd Krueger, Lauren Nicole Ambrogio
-
Publication number: 20240245602Abstract: A kit for delivering a drug formulation to treat disorders, e.g. car disorders, is disclosed. The kit includes two components: a drug formulation and a conduit for delivering the drug formulation. The kit may contain a tailored drug formulation that includes one or more of a therapeutic agent, a priming agent, an activating agent, and a reversal agent. In certain embodiments, the conduit may be provided with additional therapeutic formulations preloaded into the conduit. In some embodiments, a plug can be provided over the inner surface of the conduit where the plug contains a plug formulation.Type: ApplicationFiled: August 27, 2021Publication date: July 25, 2024Applicants: President and Fellows of Harvard College, Massachusetts Eye and Ear InfirmaryInventors: Ida PAVLICHENKO, Joanna AIZENBERG, Haritosh PATEL, Michael AIZENBERG, Cathy ZHANG, Aaron Kyle REMENSCHNEIDER, Elliot D. KOZIN
-
Publication number: 20240245603Abstract: An oral film dosage form includes a high loading of API designed to be administered in some form to a human subject and in some other form to an animal subject.Type: ApplicationFiled: February 7, 2022Publication date: July 25, 2024Applicant: Intelgenx Corp.Inventors: Billal TIR, Nadine PAIEMENT
-
Publication number: 20240245604Abstract: The present invention relates to polymeric compounds of glucuronic acid having phenolic hydroxyl moieties (herein after designated by PGU-Ph) and more particularly to a method of hydrogelation of such compounds. The present invention also relates to the use of the hydrogel structures (particles, films or 3D-structures) obtained by this method, notably as three-dimensional cell culture material to support biological molecules used as active ingredients, cell colonisation or for tissue regeneration.Type: ApplicationFiled: May 10, 2022Publication date: July 25, 2024Inventors: Cédric DELATTRE, Guillaume PIERRE, Philippe MICHAUD, Emmanuel PETIT LAIGNEL, Redouan EL BOUTACHFAITI, Shinji SAKAI
-
Publication number: 20240245605Abstract: The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.Type: ApplicationFiled: March 22, 2024Publication date: July 25, 2024Inventors: Gerard P. McNally, Vipul Dave, Anurag Pandey
-
Publication number: 20240245606Abstract: Disclosed herein are compositions comprising isolated exosomes, for instance exosomes wherein at least 20% of the exosomes comprise SDC2, methods of isolation, and methods of use.Type: ApplicationFiled: January 29, 2024Publication date: July 25, 2024Inventors: Stephen J. ELLIMAN, Jack KAVANAUGH, Larry COUTURE
-
Publication number: 20240245607Abstract: The present invention relates to compositions and methods for masking the taste of an agent. In certain aspects, the invention comprises a microsphere and at least one sweetener therein. In another aspect, the invention comprises an edible material comprising at least one microsphere comprising an agent and at least one microsphere comprising a sweetener.Type: ApplicationFiled: January 30, 2024Publication date: July 25, 2024Inventors: Gregory S. Smutzer, Kevin Lee, Dhruti Patel
-
Publication number: 20240245608Abstract: The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.Type: ApplicationFiled: April 4, 2024Publication date: July 25, 2024Inventor: Noam Emanuel
-
Publication number: 20240245609Abstract: The present invention provides a freeze-dried composition containing anti-HER2 drug conjugate, which comprises ARX788 and one or more of pharmaceutically acceptable lyoprotectant, buffer salts and surfactants, wherein the pH value of the freeze-dried composition is from 5.7 to 6.3. The present invention also provides a freeze-dried preparation containing anti-HER2 drug conjugate and the preparation method thereof. The present invention also provides use of the freeze-dried composition and the freeze-dried preparation. The freeze-dried composition and the freeze-dried preparation provided by the present invention have a very excellent stability, as well as good appearance, short reconstitution time and low moisture content. The product quality is safe and reliable, and the production efficiency is high.Type: ApplicationFiled: July 20, 2021Publication date: July 25, 2024Applicant: NOVOCODEX BIOPHARMACEUTICALS CO., LTD.Inventors: Lihai XIAO, Jiali CHEN, Moutian YE, Gang XIA, Jingjing ZHU, Lei FANG, Yuebin YING, Luxiong YE, Xuejun LIANG
-
Publication number: 20240245610Abstract: The present disclosure relates to solid oral dosage forms comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.Type: ApplicationFiled: March 1, 2024Publication date: July 25, 2024Inventors: Peng LI, Robert DAVIS, William Paul FINDLAY
-
Publication number: 20240245611Abstract: A process for preparing a polymer-coated hard shell capsule that has at least a functional coat and a top coat, suitable as container for pharmaceutical or nutraceutical biologically active ingredients can be performed. The hard shell capsule has a body and a cap, wherein in the closed state the cap overlaps the body either in a pre-locked state or in a final-locked state, wherein the hard shell capsule is provided in the pre-locked state and is coated with a first coating solution, suspension or dispersion that has at least one polymer; optionally at least one glidant; optionally at least one emulsifier; optionally at least one plasticizer; optionally at least one biologically active ingredient; and optionally at least one additive. The polymer-coated hard shell capsule obtained from the process according to the invention can be used for immediate, delayed or sustained release.Type: ApplicationFiled: May 23, 2022Publication date: July 25, 2024Applicant: Evonik Operations GmbHInventors: Hans Bär, Philipp Heller, Steven Smith, Bettina Hölzer
-
Publication number: 20240245612Abstract: Embodiments of the instant disclosure generally relate to novel compositions, methods, and systems for reducing or eliminating effects of interfering agents or premature dissolution of antigen-containing microparticles during storage, transport, and delivery of antigen-containing formulations. Certain embodiments concern improved formulations for more reliable storage, transport, delivery, and administration of metal oxide coated antigen-containing suspension formulations.Type: ApplicationFiled: April 4, 2024Publication date: July 25, 2024Inventors: Theodore Randolph, Alyssa Witeof, Robert Garcea
-
Publication number: 20240245613Abstract: The invention provides a peptide liquid droplet a composition the same and methods for the delivery of an active ingredient, as disclosed herein. The composition comprises a peptide liquid droplet and an active agent encapsulated in the peptide liquid droplet.Type: ApplicationFiled: February 5, 2024Publication date: July 25, 2024Inventors: Ayala LAMPEL, Avigail-Elah BARUCH LESHEM, Amit BEN-AMAR
-
Publication number: 20240245614Abstract: Aspects of the disclosure encompass systems, methods, and compositions for producing exosomes from mesenchymal stem cells and, optionally, loading said exosomes with one or more therapeutic agents. The systems, methods, and compositions may occur in an automated cell expansion system that allows for controllable parameters and from which cells and exosomes may be harvested at one or more times as part of a particular regimen. The exosomes may be loaded with one or more therapeutic agents using electroporation. In specific aspects, the exosomes may be provided to an individual in need thereof, including in some cases where the individual in need thereof is an individual having a medical disorder for which the exosomes would be therapeutic.Type: ApplicationFiled: May 17, 2022Publication date: July 25, 2024Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Frederick F. LANG, Elizabeth J. SHPALL, Katy REZVANI, Mayela MENDT, Daniel LEDBETTER, Joy GUMIN, Brittany PARKER KERRIGAN, Anwar HOSSAIN, Frederick M. LANG
-
Publication number: 20240245615Abstract: An implantable device for delivery of a macromolecular drug compound is provided. The device comprises a core having an outer surface and a membrane layer positioned adjacent to the outer surface of the core. The core comprises a core polymer matrix within which is dispersed a drug compound having a molecular weight of about 5 kDa or more, the polymer matrix containing a hydrophobic polymer. The membrane polymer matrix includes from about 70 wt. % to about 99 wt. % of an ethylene vinyl acetate copolymer.Type: ApplicationFiled: April 5, 2024Publication date: July 25, 2024Inventor: Christian Schneider
-
Publication number: 20240245616Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.Type: ApplicationFiled: December 28, 2023Publication date: July 25, 2024Applicant: Purdue Pharma L.P.Inventors: Ricardo Alberto VARGAS RINCON, Joseph REIZ
-
Publication number: 20240245617Abstract: This disclosure relates to a lipid-based topical injection formulation containing a Long-Acting SusTained delivering lipid, a structured lipid, a polymer-conjugated lipid and an ionizable lipid, and optionally a neutral phospholipid. The lipid-based topical injection formulation enables enriched delivery of drugs at an injection site and efficient expression of proteins for a prolonged period of time. This disclosure also relates to a method of preparing the lipid-based topical injection formulation, and use of the lipid-based topical injection formulation in the delivery of biologically active substances such as nucleic acids (e.g., mRNA, miRNA, siRNA, saRNA, ASO, DNA, etc.).Type: ApplicationFiled: May 18, 2023Publication date: July 25, 2024Inventors: Liu Yang, Jiayan Lang, Lin Zhang, Tian Jiang, Xuhui Wang, Jiani Lei, Andong Liu, Caida Lai, Wenshou Wang
-
Publication number: 20240245618Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.Type: ApplicationFiled: August 3, 2023Publication date: July 25, 2024Applicant: The Board of Regents of The University of Texas SystemInventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
-
Publication number: 20240245619Abstract: Compositions of polynucleotide(s) are disclosed. A polynucleotide may encode for a polypeptide, protein, or functional fragment thereof associated with primary ciliary dyskinesia (PCD), such as dynein axonemal intermediate chain 1 (DNAI1). Pharmaceutical compositions, kits, and methods for treating a disease or condition associated with cilia maintenance and function, and impaired function of the axoneme are also disclosed. The polynucleotide may be assembled with a lipid composition for delivery to an organ, such as the lung, of a subject. The lipid composition may comprise an ionizable cationic lipid. The polynucleotide can be expressed within cells of the organ of the subject.Type: ApplicationFiled: January 23, 2024Publication date: July 25, 2024Inventors: Vladimir Kharitonov, Bradon Wustman, Jackson Eby, Rumpa Bhattacharjee, Daniella Ishimaru, Mirko Hennig
-
Publication number: 20240245620Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.Type: ApplicationFiled: February 28, 2024Publication date: July 25, 2024Applicant: The Board of Regents of The University of Texas SystemInventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
-
Publication number: 20240245621Abstract: A method for producing a core-shell capsule for delivering a therapeutic agent is provided. The method includes printing a composite material via a nozzle on a substrate while moving the nozzle in a pre-designed pattern to create the shell of a hollow capsule. The shell defines a cavity within the hollow capsule, and the shell has an opening at an apex of an outer surface of the shell. The method includes introducing a composition, in liquid form, containing the therapeutic agent at a temperature of at least 45° C. into the cavity of the hollow capsule via the opening of the shell, and naturally cooling the composition inside the shell to solidify the composition and adhere the composition to an inner surface of the shell thereby forming a core of the core-shell capsule.Type: ApplicationFiled: January 20, 2023Publication date: July 25, 2024Applicant: NAJRAN UNIVERSITYInventors: Mohammed Saeed N. ALGAHTANI, Mohammed Abdul ALEEM, Javed AHMAD
-
Publication number: 20240245622Abstract: Implementations set forth herein relate to systems, methods, and apparatuses associated with fullerene-containing materials. In some implementations, a fullerene-containing material is disposed over a substrate of a smoke-able product in order to inhibit an allergic response (e.g., coughing) from a user who smokes or otherwise ingests the smoke-able product. Various fullerene-containing materials can be generated using a carbon substance that undergoes one or more process operations in order for fullerene molecules to be available for inclusion in the various materials. In some implementations, one or more other fullerene-containing materials can be generated through an at least partially organic process of feeding a particular plant a fullerene-containing plant food.Type: ApplicationFiled: June 12, 2023Publication date: July 25, 2024Inventor: Aaron Self
-
Publication number: 20240245623Abstract: A modular transdermal drug delivery system is provided, the system including: an upper module in which an outer backing layer is laminated to a pressure-sensitive adhesive layer that is covered by a removable release liner prior to assembly; and a lower module with a porous drug reservoir layer laminated to a skin-contact adhesive that affixes the system to the skin during drug delivery, where the skin-contact adhesive is, in one embodiment, an adhesive layer that is substantially co-extensive with the porous drug reservoir layer and, prior to use, protected with a second removable release liner. Methods of manufacture and use are also provided, as is an assembled transdermal drug delivery system fabricated by affixing the pressure-sensitive adhesive layer of the upper module to the porous drug reservoir layer of the lower module.Type: ApplicationFiled: September 1, 2023Publication date: July 25, 2024Inventor: Frank Kochinke
-
Publication number: 20240245624Abstract: The present invention is directed to a composition comprising phytoene, phytofluene, and zeta carotene, and methods of using the same, such as for improving skin barrier functionality.Type: ApplicationFiled: June 16, 2022Publication date: July 25, 2024Inventor: Nava DAYAN
-
Publication number: 20240245625Abstract: The present disclosure provides methods of treatment using ophthalmic compositions comprising semifluorinated alkanes for keratoconjunctivitis sicca and/or Meibomian gland dysfunction, which methods provide for the enrichment of an ophthalmic tissue in the semifluorinated alkane, and optionally methods of delayed release of the semifluorinated alkane from the enriched ophthalmic tissue to the surface of the cornea and/or conjunctiva, and/or to the Meibomian gland.Type: ApplicationFiled: February 12, 2024Publication date: July 25, 2024Inventors: Bernhard GÜNTHER, Frank LÖSCHER, Hartmut VOSS, Sonja KRÖSSER, Kirsten EICKHOFF, Daniela WILLEN, Markus BEIER, Thomas SCHLÜTER
-
Publication number: 20240245626Abstract: The present disclosure provides pharmaceutical compositions for oral administration of propofol as well as methods of treatment using such pharmaceutical compositions.Type: ApplicationFiled: February 21, 2024Publication date: July 25, 2024Inventors: Steven L. KRILL, Feng-Jing CHEN
-
Publication number: 20240245627Abstract: Disclosed herein are new pharmacological therapies that increase CYB5R3 activity, improve vascular function and limit inflammation by restoring the redox balance in CVD. In one embodiment, disclosed herein are compounds that include an alkyl chain containing a nitroalkene group conjugated to a quinone-containing moiety.Type: ApplicationFiled: March 24, 2022Publication date: July 25, 2024Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Adam C. Straub, Bruce A. Freeman, Francisco J. Schopfer
-
Publication number: 20240245628Abstract: The present disclosure describes compositions comprising vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin, and coenzyme Q10, and pharmaceutically acceptable salts of any of the foregoing. The compositions are useful in methods for treating conditions associated with a loss of visual acuity including, for example, age-related macular degeneration as well as supporting heart health.Type: ApplicationFiled: January 2, 2024Publication date: July 25, 2024Inventors: Daniel STEIN, Christopher CORTINA
-
Publication number: 20240245629Abstract: This disclosure provides a method of reducing steroid use, all-cause hospitalization, and/or advanced therapy use in a subject diagnosed inflammatory bowel disease, Crohn's disease, or ulcerative colitis. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of atovaquone or a salt thereof in combination with proguanil or a salt thereof.Type: ApplicationFiled: February 16, 2024Publication date: July 25, 2024Applicant: Elevaid Therapeutics, Inc.Inventor: Joseph David
-
Publication number: 20240245630Abstract: Novel dual use compositions for the obscuring and soothing of tender pigment imperfections are disclosed. These pre-mixed compositions represent a significant aesthetic improvement over the prior art, as well as exhibiting increased resilience over said prior art. In addition to their cosmetic properties, said novel compositions possess and exhibit analgesic properties, and include a topical analgesic for addressing cold sores, a waxy ingredient, a colorant or pigment, and a stabilizer.Type: ApplicationFiled: January 10, 2024Publication date: July 25, 2024Inventors: Alexandra Evelyn Mora, Fadi Mourad
-
Publication number: 20240245631Abstract: A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient. Lennox Syndrome patients are treated at a preferred dose of less than about 2.0 to about 0.01 mg/kg/day.Type: ApplicationFiled: January 19, 2024Publication date: July 25, 2024Inventors: Stephen J. FARR, Bradley S. GALER
-
Publication number: 20240245632Abstract: The present disclosure provides methods of treating substance use disorders comprising the oral administration mescaline or a salt thereof. In another aspect, the oral administration comprises a pharmaceutical composition comprising synthetic mescaline. The synthetic mescaline, mescaline or salts thereof, and pharmaceutical compositions disclosed herein, provide several advantages over plant extracted mescaline. For example, plant extractions can have varying concentrations of active mescaline leading to dosing variability and potency. In additional embodiments, the administration is accompanied with a preparatory therapy session. In another aspect, the method further comprises a plurality of treatment steps to aid in the efficacy of treating substance use disorders.Type: ApplicationFiled: May 27, 2022Publication date: July 25, 2024Inventors: Jeeshan Chowdhury, Derek Londesbrough, Christopher Gill
-
Publication number: 20240245633Abstract: The T cell specific RORgamma isoform RORgammat has been shown to be the key lineage-defining transcription factor to initiate the differentiation program of TH17 and TC17 cells, cells that have demonstrated anti-tumor efficacy, RORgammat controls gene networks that enhance immunity including increased IL17 production and decreased immune suppression. Agonists of RORgammat have been shown to increase the basal activity of RORgammat enhancing TH17 cell proliferation. Here we show that activation of RORgammat using synthetic agonists drives proliferation of cells while decreasing levels of the immune checkpoint protein PD-1, a mechanism that should enhance anti-tumor immunity while blunting tumor associated adaptive immune resistance. Interestingly, putative endogenous agonists drive proliferation of TH17 cells but do not repress PD-1.Type: ApplicationFiled: November 1, 2016Publication date: July 25, 2024Inventors: Patrick Griffin, Theodore Kamenecka, Mi Ra Chang, Christelle Doebelin
-
Publication number: 20240245634Abstract: Described herein are, inter alia, methods of treating cancer using an EGFR-TK inhibitor and a PCNA inhibitor, and pharmaceutical compositions comprising an EGFR-TK inhibitor and a PCNA inhibitor.Type: ApplicationFiled: April 29, 2022Publication date: July 25, 2024Inventors: Robert Lingeman, Linda H. Malkas, Robert J. Hickey
-
Publication number: 20240245635Abstract: The present invention provides a patch that suppresses the generation of a degradation product of loxoprofen and shows excellent skin permeability, and a method for producing the same. Specifically, the present invention provides a patch comprising loxoprofen or a salt thereof, or a hydrate thereof; a C2-C6 hydroxy acid; and a metal oxide in a pasty preparation, and a method for producing the same.Type: ApplicationFiled: March 3, 2022Publication date: July 25, 2024Applicant: TEIKOKU SEIYAKU CO., LTD.Inventor: Yuki HARAUCHI
